Invokana
Invokana is an originator product from Janssen-Cilag AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 50.35 to CHF 186.30 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Janssen-Cilag AG
- ATC code
- A10BK02
- IT group
- 07.06.20 Orale blutzuckersenkende Mittel
- Active substances
- Canagliflozinum
- Preparation type
- Originator product
- On the SL since
- 01/03/2014
- Last price change
- 01/08/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl 100 mg | 30 Stk | CHF 31.21 | CHF 50.35 | 01/03/2014 | B | 7680629560029 |
| Filmtabl 100 mg | 100 Stk | CHF 100.44 | CHF 125.65 | 01/03/2014 | B | 7680629560043 |
| Filmtabl 300 mg | 30 Stk | CHF 48.16 | CHF 68.80 | 01/03/2014 | B | 7680629560067 |
| Filmtabl 300 mg | 100 Stk | CHF 156.22 | CHF 186.30 | 01/03/2014 | B | 7680629560081 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Zur Behandlung von erwachsenen Patienten mit einem Typ 2 Diabetes mellitus zur Verbesserung der glykämischen Kontrolle, wenn durch Diät und gesteigerte körperliche Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird:
- Als Monotherapie bei Patienten, die nicht mit Metformin behandelt werden können.
- In Kombination mit:
- Metformin
- einem Sulfonylharnstoff
- einem DPP4-Inhibitor (mit oder ohne Metformin)
- einem GLP-1-Analogon (mit oder ohne Metformin)
- Insulin, alleine oder in Kombination mit Metformin und/oder Sulfonylharnstoff.
FAQ
Is Invokana covered by Swiss health insurance?
Yes, but only under conditions. Invokana is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Invokana cost in Switzerland?
The public price is the maximum price set by the FOPH and for Invokana ranges from CHF 50.35 to CHF 186.30 per pack. The ex-factory price ranges from CHF 31.21 to CHF 156.22. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages